Thibaut BARBIER obtained his master’s degree in Drug sciences at Université Clermont Auvergne in 2019. His M1’s internship was done in 2018 under the supervision of Prof Sylvie DUCKI (ICCF, Clermont-Ferrand), aiming at the discovery of new analgesic compounds. His M2’s internship concerned the development of ABCG2 efflux pump inhibitors against cancer cells and was done in collaboration between the chemistry team of Prof Marc LE BORGNE (EA4446, Lyon) and the biology team of Dr Pierre FALSON (MMSB, Lyon). Since October 2019, he does a PhD in COB team at ICBMS under the supervision of Dr Laurent SOULÈRE and Dr Yves QUENEAU, combining molecular modelling, organic synthesis and microbiology aiming at the discovery of new compounds against Staphylococcus aureus and SARS-CoV-2.
During his curriculum, Thibaut’s work successively concerned the research of analgesic, anti-cancerous and anti-infectious molecules. During his PhD, his focus is on the inhibition of FtsZ, key protein for bacterial division. Molecular modelling studies are also undertaken to identify potential inhibitors for the main protease of SARS-CoV-2, an essential protein for viral replication.
Barbier, T.; Barbry, A.; Magand, J.; Badiou, C.; Davy, F.; Baudouin, A.; Queneau, Y.; Dumitrescu, O.; Lina, G.; Soulère, L. Synthesis and Biological Evaluation of Benzo[b]Thiophene Acylhydrazones as Antimicrobial Agents against Multidrug-Resistant Staphylococcus Aureus. Biomolecules 2022, 12 (1), 131.
Soulère, L.; Barbier, T.; Queneau, Y. Docking-Based Virtual Screening Studies Aiming at the Covalent Inhibition of SARS-CoV-2 MPro by Targeting the Cysteine 145. Comput. Biol. Chem. 2021, 92, 107463.